Preventing leaks is also important because some medications can cause irritation or discoloration if they leak into the subcutaneous ... children, the best place to administer an intramuscular ...

An oncology nurse shares advice for avoiding exhaustion and soreness when administering subcutaneous injections.

The injection is given in the thigh or abdomen. The dosage is based on your medical condition and response to treatment. Children's dosage is also based on weight. If you are using this medication ...

Traditionally, hemophilia with inhibitors has been managed with intravenous (IV) infusions; concizumab shifts the paradigm with a subcutaneous injection ... for adults and children 12 years ...

The FDA approved ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo; Genentech), a twice-yearly subcutaneous injection, for relapsing multiple sclerosis (RMS) and primary progressive multiple ...

The Food and Drug Administration (FDA) approved Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), a subcutaneous injection, for all previously approved indications of the intravenous ...

Ocrevus Zunovo is the first and only twice-a-year, healthcare professional (HCP)-administered approximately 10-minute subcutaneous (SC) injection approved for both these forms of multiple ...

The study met its primary endpoints, demonstrating noninferior pharmacokinetics (PK) for subcutaneous pembrolizumab administered with chemotherapy with a median injection time of two minutes ...

The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection. The agent (Tecentriq Hybreza, Genentech) is the first subcutaneous anti-PD-L1 cancer immunotherapy approved in the ...

Notably, this interview came following the Dec. 27, 2024, Food and Drug Administration (FDA) approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. Intravenous ...